financetom
Business
financetom
/
Business
/
EU regulators ask if Starlink is credible rival to SES, Intelsat
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
EU regulators ask if Starlink is credible rival to SES, Intelsat
May 26, 2025 6:07 AM

BRUSSELS (Reuters) -EU antitrust regulators, who are examining European satellite company SES's $3.1-billion bid for Intelsat, have asked the two companies' customers whether Elon Musk's Space X-owned Starlink is a credible rival to them.

The responses, due on Monday, will determine whether the European Commission, the EU executive, clears the deal with or without concessions or opens a full-scale investigation if it has serious concerns.

SES operates a multi-orbit fleet of around 70 satellites that provide services, including video broadcasting, government communications and broadband internet.

As the European Union seeks to develop an alternative to the U.S. companies, SES in common with other European satellite companies is seeking greater scale to better compete with Starlink and Amazon's Project Kuiper.

In a questionnaire sent to third parties and seen by Reuters, the EU competition watchdog asked if low-earth orbit satellites, such as those of Starlink and Eutelsat's OneWeb, are credible rivals for the supply of two-way satellite capacity.

They also wanted to know if low-earth orbit suppliers are taking part in tenders and customer contracts and winning them, and how they will affect competition in the next five years.

Respondents were asked whether they have the negotiating and bargaining power to secure favourable terms and conditions when purchasing two-way satellite capacity from SES and Intelsat, and if they can easily switch to a rival supplier.

The Commission has set a June 10 for its preliminary review of the deal.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Japan's union group Rengo announces biggest wage hikes on record
Japan's union group Rengo announces biggest wage hikes on record
Mar 22, 2024
TOKYO (Reuters) -Japanese firms have agreed to raise pay by 5.25% this year, the biggest rise under comparable data since 2013, the country's largest union group Rengo confirmed on Friday. The results of the closely-watched wage negotiations are announced in several stages, in which the blue-chip firms are first to wrap up their talks in mid-March. The second announcement on...
Once a beacon of stability, Vietnam to name third president in a year
Once a beacon of stability, Vietnam to name third president in a year
Mar 22, 2024
HANOI, March 22 (Reuters) - Communist-ruled Vietnam is seeking its third president in little more than a year after the resignation of Vo Van Thuong, who was only elected last year after the sudden dismissal of his predecessor. With accumulated foreign direct investment higher than its gross domestic product, Vietnam's stability is crucial to multinationals with large operations in the...
Cathie Wood's ARK Invest scoops up nearly 10,000 Reddit shares in debut
Cathie Wood's ARK Invest scoops up nearly 10,000 Reddit shares in debut
Mar 22, 2024
(Reuters) - Popular investor Cathie Wood's ARK Invest bought nearly 10,000 shares of Reddit ( RDDT ) in the social media platform's strong market debut on Thursday, an email from the asset manager showed. A total of 9,982 shares of the loss-making company was added to ARK Next Generation Internet ETF ( ARKW ) and ARK Fintech Innovation ETF (...
Hutchmed Begins Registration Stage for Phase 2/3 Trial of Investigational Autoimmune Disorder Drug
Hutchmed Begins Registration Stage for Phase 2/3 Trial of Investigational Autoimmune Disorder Drug
Mar 22, 2024
05:04 AM EDT, 03/22/2024 (MT Newswires) -- Hutchmed ( HCM ) said late Thursday it has started the registration stage for a phase 2/3 clinical trial of investigational drug sovleplenib for adult patients with warm antibody autoimmune hemolytic anemia in China. The move follows positive data from the proof-of-concept phase 2 stage of the trial and a consultation with the...
Copyright 2023-2026 - www.financetom.com All Rights Reserved